Home › RLT targets by cancer › Pancreatic Cancer
Radioligand therapy · Pancreatic Cancer

Radioligand Therapy Targets in Pancreatic Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in pancreatic cancer (including pancreatic ductal adenocarcinoma (PDAC)). 4,471 show detectable protein staining. Established and emerging radioligand targets expressed in pancreatic cancer include HER3 (ERBB3), FAP, STEAP2 and c-MET (MET). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own pancreatic cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank pancreatic cancer targets free

Established and emerging radioligand targets in pancreatic cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in pancreatic cancer:

TargetIHC in pancreatic cancer% positiveInternalizes
HER3 (ERBB3)High (0.88)100%yes
FAPHigh (0.74)89%yes
STEAP2High (0.70)100%—
c-MET (MET)High (0.67)100%yes
Mesothelin (MSLN)High (0.64)83%yes
EGFRHigh (0.64)100%yes
CEA (CEACAM5)High (0.64)91%—
B7-H3 (CD276)High (0.56)100%—
ITGAVHigh (0.56)89%—
ITGB6Medium (0.37)70%—
SSTR2Medium (0.31)58%yes
Claudin 18.2 (CLDN18)Medium (0.30)40%uncertain
TMEFF2Medium (0.25)67%—
Nectin-4 (NECTIN4)Medium (0.22)42%no
HER2 (ERBB2)Low (0.18)46%yes
TROP2 (TACSTD2)Low (0.12)27%uncertain
DLK1Low (0.06)8%—
EPCAMLow (0.04)11%—
CAIX (CA9)Low (0.03)10%no
CD19Low (0.03)10%—
PSMA (FOLH1)Low (0.03)8%yes
KITLow (0.03)8%no

Top cell-surface targets for pancreatic cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in pancreatic cancer% positiveInternalizesClinical stage
1EGFR
epidermal growth factor receptor
High (0.64)100%yesFDA-Approved
2HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.88)100%yesFDA-Approved
3CYSLTR2
cysteinyl leukotriene receptor 2
High (0.94)100%yesDiscovery
4IGF1R
insulin like growth factor 1 receptor
High (0.82)100%yesFDA-Approved
5c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.67)100%yesFDA-Approved
6AMFR
autocrine motility factor receptor
High (1.00)100%yesDiscovery
7NOTCH1
notch receptor 1
High (0.75)100%yesClinical
8MAOB
monoamine oxidase B
High (0.94)100%—FDA-Approved
9GPR139
G protein-coupled receptor 139
High (0.94)100%yesDiscovery
10NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.80)100%uncertainFDA-Approved
11LIFR
LIF receptor subunit alpha
High (0.88)100%yesDiscovery
12Mesothelin (MSLN)
mesothelin
High (0.64)83%yesClinical
13HRH4
histamine receptor H4
High (0.70)100%yesClinical
14IRAK4
interleukin 1 receptor associated kinase 4
High (0.70)100%yesClinical
15EPHB2
EPH receptor B2
High (0.69)100%uncertainFDA-Approved
16ITPR3
inositol 1,4,5-trisphosphate receptor type 3
High (0.83)100%yesDiscovery
17S1PR1
sphingosine-1-phosphate receptor 1
Medium (0.42)83%yesFDA-Approved
18FGFR1
fibroblast growth factor receptor 1
High (0.52)100%yesFDA-Approved
19MST1R
macrophage stimulating 1 receptor
High (0.53)100%yesFDA-Approved
20VIPR1
vasoactive intestinal peptide receptor 1
High (0.61)100%yesDiscovery
21IL1R2
interleukin 1 receptor type 2
High (0.61)92%yesDiscovery
22FZD6
frizzled class receptor 6
High (0.77)100%yesDiscovery
23GABRE
gamma-aminobutyric acid type A receptor subunit epsilon
High (0.81)100%uncertainFDA-Approved
24CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.58)100%yesClinical
25AGTRAP
angiotensin II receptor associated protein
High (0.75)92%yesDiscovery

Internalizing receptors in pancreatic cancer

Targets expressed in pancreatic cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

EGFR · HER3 (ERBB3) · CYSLTR2 · IGF1R · c-MET (MET) · AMFR · NOTCH1 · GPR139 · LIFR · Mesothelin (MSLN) · HRH4 · IRAK4

Pancreatic Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in pancreatic cancer. Clinical precedent lowers development risk but usually means more competition:

EGFR · HER3 (ERBB3) · IGF1R · c-MET (MET) · NOTCH1 · MAOB · NR3C2 · Mesothelin (MSLN) · HRH4 · IRAK4 · EPHB2 · S1PR1

How these pancreatic cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in pancreatic cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank pancreatic cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free pancreatic cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist pancreatic cancer targets for your program · 5 free analyses, no card Rank pancreatic cancer targets free